Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker
- Conditions
- Interventions
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 94
- Registration Number
- NCT04334941
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT04322643
- Locations
- 🇺🇸
Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 34
- Registration Number
- NCT04321330
- Locations
- 🇨🇳
West China Hospital, Sichuan University; Department of Breast, Chengdu, China
🇨🇳Sichuan Cancer Hospital, Chengdu City, China
🇨🇳The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 47
- Registration Number
- NCT04310020
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-16
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT04308785
- Locations
- 🇨🇳
Anhui Province Cancer Hospital, Hefei City, China
🇨🇳Guangxi Cancer Hospital of Guangxi Medical University, Nanning, China
🇨🇳Tianjin Cancer Hospital, Tianjin, China
A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 189
- Registration Number
- NCT04303858
- Locations
- 🇪🇸
Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain
🇧🇪UZ Leuven Gasthuisberg, Leuven, Belgium
🇪🇸Vall d?Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, Spain
A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT04302025
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸UCLA Hematology Oncology, Los Angeles, California, United States
🇺🇸Karmanos Cancer Institute - Farmington Hills/Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States
A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 172
- Registration Number
- NCT04300647
- Locations
- 🇺🇸
Kaiser Permanente - Irvine, Irvine, California, United States
🇺🇸Oncology Associates of Oregon, P.C, Eugene, Oregon, United States
🇦🇺Mater Misericordiae Limited, South Brisbane, Queensland, Australia
A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 620
- Registration Number
- NCT04294810
- Locations
- 🇺🇸
US oncology research at Minnesota Oncology, Saint Paul, Minnesota, United States
🇺🇸Onc & Hem Assoc SW Virginia, Salem, Virginia, United States
🇦🇺Austin Hospital Olivia Newton John Cancer Centre, Heidelberg, Victoria, Australia
Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-28
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Deepak Kilari
- Target Recruit Count
- 46
- Registration Number
- NCT04289779
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.